Acquired by Novo Holdings and Gurnet Point in Oct 2023
PRTK - Paratek Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
PRTK price evolution
PRTK
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $42.81 | $45.15 | $34.37 | $27.21 |
| Short term investments | $29.92 | |||
| Net receivables | $42.51 | $37.17 | $78.04 | $32.74 |
| Inventory | $47.8 | $49.58 | $16.57 | $53.87 |
| Total current assets | $105.23 | $111.01 | $136.84 | $121.34 |
| Long term investments | ||||
| Property, plant & equipment | $2.2 | $2.24 | $2.4 | $1.79 |
| Goodwill & intangible assets | $0.83 | $0.83 | $0.83 | $0.83 |
| Total noncurrent assets | $40.56 | $39.81 | $35.7 | $35.98 |
| Total investments | $29.92 | |||
| Total assets | $145.79 | $150.83 | $172.54 | $157.32 |
| Current liabilities | ||||
| Accounts payable | $2.95 | $5.32 | $5.31 | $8.11 |
| Deferred revenue | ||||
| Short long term debt | $164.04 | |||
| Total current liabilities | $202.62 | $32.74 | $37.39 | $38.98 |
| Long term debt | $95.71 | $259.07 | $256.95 | $259.1 |
| Total noncurrent liabilities | $144.54 | $307.12 | $306.19 | $284.5 |
| Total debt | $259.76 | $259.07 | $258.41 | $259.1 |
| Total liabilities | $347.16 | $339.87 | $343.58 | $323.47 |
| Shareholders' equity | ||||
| Retained earnings | -$965.14 | -$950.59 | -$930.45 | -$923.29 |
| Other shareholder equity | -$0.12 | |||
| Total shareholder equity | -$201.37 | -$189.04 | -$171.04 | -$166.15 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $34.37 | $80.49 | $106.05 | $102.63 |
| Short term investments | $15.11 | $20 | $113.08 | |
| Net receivables | $78.04 | $33.12 | $15.73 | $9.58 |
| Inventory | $16.57 | $38.79 | $14.55 | $11.58 |
| Total current assets | $136.84 | $152.1 | $164.12 | $243.35 |
| Long term investments | $0.13 | $3.01 | ||
| Property, plant & equipment | $2.4 | $2.55 | $2.97 | $3.74 |
| Goodwill & intangible assets | $0.83 | $0.83 | $0.83 | $0.83 |
| Total noncurrent assets | $35.7 | $31.77 | $12.74 | $7.72 |
| Total investments | $15.23 | $20 | $116.08 | |
| Total assets | $172.54 | $183.87 | $176.85 | $251.08 |
| Current liabilities | ||||
| Accounts payable | $5.31 | $5.39 | $1.81 | $4.12 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $37.39 | $31.3 | $23.95 | $24.2 |
| Long term debt | $256.95 | $255.74 | $252.02 | $262.82 |
| Total noncurrent liabilities | $306.19 | $280.36 | $255.16 | $266.53 |
| Total debt | $258.41 | $255.74 | $252.02 | $262.82 |
| Total liabilities | $343.58 | $311.66 | $279.11 | $290.73 |
| Shareholders' equity | ||||
| Retained earnings | -$930.45 | -$866.88 | -$807.8 | -$711.26 |
| Other shareholder equity | -$0.01 | $0 | $0.07 | |
| Total shareholder equity | -$171.04 | -$127.79 | -$102.26 | -$39.65 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $39.99 | $31.24 | $75.56 | $30.21 |
| Cost of revenue | $4.37 | $6.24 | $10.31 | $4.37 |
| Gross Profit | $35.63 | $24.99 | $65.25 | $25.84 |
| Operating activities | ||||
| Research & development | $8.77 | $7.31 | $14.27 | $8.49 |
| Selling, general & administrative | $36.26 | $33.49 | $53.81 | $33.85 |
| Total operating expenses | $45.04 | $40.8 | $68.08 | $42.33 |
| Operating income | -$9.41 | -$15.8 | -$2.84 | -$16.49 |
| Income from continuing operations | ||||
| EBIT | -$9.21 | -$15.61 | -$2.54 | -$16.34 |
| Income tax expense | $0.05 | $0.06 | $0.06 | |
| Interest expense | $5.29 | $4.48 | $4.56 | $4.54 |
| Net income | ||||
| Net income | -$14.55 | -$20.14 | -$7.16 | -$20.88 |
| Income (for common shares) | -$14.55 | -$20.14 | -$7.16 | -$20.88 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $160.27 | $130.16 | $46.92 | $16.54 |
| Cost of revenue | $23.06 | $21.54 | $8.65 | $3.48 |
| Gross Profit | $137.21 | $108.63 | $38.27 | $13.06 |
| Operating activities | ||||
| Research & development | $37.82 | $30.35 | $23.92 | $39.55 |
| Selling, general & administrative | $145.6 | $119.4 | $89.86 | $89.14 |
| Total operating expenses | $183.42 | $149.76 | $113.78 | $128.69 |
| Operating income | -$46.21 | -$41.13 | -$75.5 | -$115.63 |
| Income from continuing operations | ||||
| EBIT | -$45.39 | -$41.08 | -$76.3 | -$112.09 |
| Income tax expense | $0.06 | $0.6 | $0.3 | |
| Interest expense | $18.12 | $17.41 | $20.24 | $16.4 |
| Net income | ||||
| Net income | -$63.57 | -$59.08 | -$96.54 | -$128.79 |
| Income (for common shares) | -$63.57 | -$59.08 | -$96.54 | -$128.79 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | -$14.55 | -$20.14 | -$7.16 | -$20.88 |
| Operating activities | ||||
| Depreciation | $0.05 | $0.05 | $0.09 | $0.13 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.23 | $2.15 | $1.99 | $3.98 |
| Total cash flows from operations | -$1.78 | $11.09 | -$20.11 | -$12.42 |
| Investing activities | ||||
| Capital expenditures | -$0.03 | |||
| Investments | $30 | |||
| Total cash flows from investing | -$0.03 | $30 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.16 | $0 | ||
| Net borrowings | -$0.56 | -$0.28 | -$2.89 | |
| Total cash flows from financing | -$0.56 | -$0.28 | -$2.73 | $0 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.34 | $10.78 | $7.16 | -$12.42 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$63.57 | -$59.08 | -$96.54 | -$128.79 |
| Operating activities | ||||
| Depreciation | $0.49 | $0.39 | $0.58 | -$1.29 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.32 | $14.34 | $10.25 | $14.29 |
| Total cash flows from operations | -$66.14 | -$48.27 | -$103.42 | -$134.04 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.37 | -$0.38 | -$0.24 |
| Investments | $14.84 | $4.88 | $92.88 | $134.79 |
| Total cash flows from investing | $14.8 | $4.51 | $92.5 | $134.55 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.98 | $19.05 | $22.62 | $27.07 |
| Net borrowings | -$2.89 | -$0.72 | -$11.28 | $30.55 |
| Total cash flows from financing | $5.09 | $18.33 | $11.34 | $57.62 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$46.24 | -$25.43 | $0.41 | $58.13 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 57.28M |
| Revenue | $177.00M |
|---|---|
| EBITDA | -$43.40M |
| EBIT | -$43.71M |
| Net Income | -$62.73M |
| Revenue Q/Q | 34.94% |
| Revenue Y/Y | 59.83% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -3.52 |
| Cash/Share | 0.75 |
| EPS | -$1.10 |
|---|---|
| ROA | -40.05% |
| ROE | 34.49% |
| Debt/Equity | -2.01 |
|---|---|
| Net debt/EBITDA | -7.01 |
| Current ratio | 0.52 |
| Quick ratio | 0.28 |